| 摘要: |
| 当前，新型冠状病毒（2019-nCoV）感染引发的肺炎疫情已经发展为严重的公共卫生安全问题。针对该病毒，目前临床上并没有针对性的抗病毒药物。瑞德西韦（remdesivir，GS-5734）是由美国吉利德科学公司（Gilead Science）研制的一种新型核苷酸类似物抗病毒药。由于瑞德西韦在抗同属冠状病毒的非典型性肺炎冠状病毒（SARS-CoV）和中东呼吸综合症冠状病毒（MERS-CoV）中表现出较好的作用，一项针对其抗2019-nCoV的临床试验已经在中国启动。本文就该药物的基本信息、作用机制、药动学、国内外研究现状等方面进行概述，以期为临床用药提供参考。 |
| 关键词: 新型冠状病毒 瑞德西韦 临床研究 |
| DOI：10.13748/j.cnki.issn1007-7693.2020.03.002 |
| 分类号:R978.7 |
| 基金项目: |
|
| Potential Anti 2019-nCoV Drug: Remdesivir |
|
XU Zijin1,2, WANG Ping2
|
|
1.Department of Pharmacy, Jiangxi Medical College, Shangrao 314000, China;2.School of pharmacy, Zhejiang University of technology, Hangzhou 310000, China
|
| Abstract: |
| At present, the pneumonia caused by the novel coronavirus (2019-nCoV) infection has developed into a serious public health and safety problem. Currently, there is no targeted antiviral drugs for the virus. Remdesivir (GS-5734) is a new nucleotide analogue antiviral drug developed by Gilead science. The targeted clinical trials against 2019-CoV have been launched in China as remdesivir has shown a good effect in anti SARS-CoV and MERS-CoV. In this paper, the basic information, mechanism of action, pharmacokinetics, research status in domestic and international of remdesivir are summarized in order to provide reference for clinical medication. |
| Key words: 2019-nCoV remdesivir clinical research |
